Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer

被引：0
|
作者：
Katsuhiko Nakatsukasa
Hiroshi Koyama
Yoshimi Oouchi
Seiichi Imanishi
Naruhiko Mizuta
Kouichi Sakaguchi
Yoshifumi Fujita
Aya Imai
Akiko Okamoto
Asako Hamaoka
Mari Soushi
Ikuya Fujiwara
Tatsuya Kotani
Takayuki Matsuda
Kenichirou Fukuda
Midori Morita
Sadao Kawakami
Yayoi Kadotani
Eiichi Konishi
Akio Yanagisawa
Mariko Goto
Kei Yamada
Tetsuya Taguchi
机构：
[1] Kyoto Prefectural University of Medicine,Department of Endocrine and Breast Surgery
[2] Nara City Hospital,Department of Surgical Pathology
[3] Ayabe City Hospital,Department of Radiology
[4] Saiseikai Kyoto Hospital,undefined
[5] Saiseikai Shiga Hospital,undefined
[6] Fukuchiyama City Hospital,undefined
[7] Aiseikai Yamashina Hospital,undefined
[8] Kyoto Prefectural University of Medicine,undefined
[9] Kyoto Prefectural University of Medicine,undefined
来源：
Breast Cancer | 2017年 / 24卷
关键词：
Breast cancer; Human epidermal growth factor receptor 2-positive; Neoadjuvant chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：92 / 97
页数：5
相关论文
共 50 条
  • [41] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    [J]. LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [42] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Giampaolo Bianchini
    Astrid Kiermaier
    Giulia Valeria Bianchi
    Young-Hyuck Im
    Tadeusz Pienkowski
    Mei-Ching Liu
    Ling-Ming Tseng
    Mitch Dowsett
    Lila Zabaglo
    Sarah Kirk
    Tania Szado
    Jennifer Eng-Wong
    Lukas C. Amler
    Pinuccia Valagussa
    Luca Gianni
    [J]. Breast Cancer Research, 19
  • [43] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [44] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    [J]. LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [45] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [46] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    [J]. ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [47] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Bianchini, Giampaolo
    Kiermaier, Astrid
    Bianchi, Giulia Valeria
    Im, Young-Hyuck
    Pienkowski, Tadeusz
    Liu, Mei-Ching
    Tseng, Ling-Ming
    Dowsett, Mitch
    Zabaglo, Lila
    Kirk, Sarah
    Szado, Tania
    Eng-Wong, Jennifer
    Amler, Lukas C.
    Valagussa, Pinuccia
    Gianni, Luca
    [J]. BREAST CANCER RESEARCH, 2017, 19
  • [48] Distichiasis in association with entropion in metastatic HER2-positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy
    Tas, Faruk
    Ozturker, Can
    [J]. BREAST JOURNAL, 2020, 26 (05): : 1004 - 1006
  • [49] Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
    Rocca, Andrea
    Cortesi, Pietro
    Cortesi, Laura
    Gianni, Lorenzo
    Matteucci, Federica
    Fantini, Lorenzo
    Maestri, Antonio
    Giunchi, Donata Casadei
    Cavanna, Luigi
    Ciani, Rosa
    Falcini, Fabio
    Bagni, Antonella
    Meldoli, Elena
    Dall'Agata, Monia
    Volpi, Roberta
    Andreis, Daniele
    Nanni, Oriana
    Curcio, Annalisa
    Lucchi, Leonardo
    Amadori, Dino
    Fedeli, Anna
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [50] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    [J]. BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
12345